Longevity Vision Fund
PE / VC · New York · United States
Stages
Investment region
Industries
Profile
Longevity Vision Fund is a venture capital firm based in New York, founded in 2019. The firm focuses on investing in technologies that aim to extend human lifespan and improve health. With a small team of professionals, they are dedicated to supporting breakthroughs in longevity and healthcare, distinguishing themselves by their commitment to making these advancements accessible and affordable. The fund primarily invests in sectors such as preventive medicine, medical technologies, artificial intelligence in healthcare, longevity therapies, and regenerative medicine. They typically engage in Series A to C funding rounds, focusing on companies within the United States. Their portfolio includes investments in companies like Biolinq, Senda Biosciences, and Tessera Therapeutics. Longevity Vision Fund I, launched in 2020, manages assets worth $100 million. Notable investments by Longevity Vision Fund include Biolinq - monitoring equipment, Senda Biosciences - biotechnology, Tessera Therapeutics - drug delivery, LyGenesis - drug discovery, and Eko - monitoring equipment. These companies reflect the fund's focus on innovative health technologies and longevity solutions.
Contacts (2)
| Name | Title | Phone | ||
|---|---|---|---|---|
| Founder | — | — | — | |
| Venture Partner & Head of Innovation | — | — | — |
Name, email and phone are partially hidden. Subscribe to see them in full.